Glycol vapors—specifically propylene glycol (PG), dipropylene glycol (DPG), and triethylene glycol (TEG)—are abundant, widely used compounds found in everyday products from cosmetics to food to theatrical fog. Manufactured at industrial scales and used for decades in consumer applications, these compounds also possess powerful antimicrobial properties when vaporized into indoor air. Blueprint Biosecurity is currently exploring glycol vapors as a neglected but promising emergency tool for airborne disinfection. At invisible and odorless concentrations, glycol vapors have been shown to rapidly inactivate a wide range of viruses, bacteria, and fungi. In a severe disease outbreak where conventional tools like PPE and ventilation may be insufficient, glycols could offer a rapidly deployable, low-cost, and minimally disruptive layer of protection, especially for safeguarding critical infrastructure operations.
Publication: Developing a Customer Screening Framework for the Life Sciences
Introduction
Since the 1970’s and the advent of recombinant DNA, biology has consistently become easier to engineer, and the pace of these advances is increasing. Many tools and capabilities for engineering biology are becoming more powerful, more affordable, and more widely available. These capabilities are critical for basic scientific research as well as advances in health, agriculture, and a wide range of applications in the burgeoning bioeconomy. However, access to these tools also raises the possibility that they could be accidentally or deliberately misused to cause harm by enabling development of toxins, pathogens, or other dangerous biological agents, including some not found in nature. Potential biological harms include high-consequence events such as the development and release of an engineered pathogen that causes a global catastrophe as well as a wide range of lower-consequence, higher-likelihood events. To prevent this type of misuse, policy experts have recommended expanding customer screening practices and policy frameworks to include a broad range of life sciences products, services, and infrastructure (Carter and DiEuliis, 2019a). Recent advances in artificial intelligence (AI) have increased this type of risk and have intensified these calls for action (Carter, et al., 2023; Helena, 2023).